These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 20434022)

  • 21. Research dishonesty and conflict of interest.
    Frizelle F
    N Z Med J; 2002 Dec; 115(1167):U270. PubMed ID: 12552259
    [No Abstract]   [Full Text] [Related]  

  • 22. Bias in the design, interpretation, and publication of industry-sponsored clinical research.
    Hammerschmidt D
    Minn Med; 2008 Jun; 91(6):46-7. PubMed ID: 18616022
    [No Abstract]   [Full Text] [Related]  

  • 23. Why the Cochrane risk of bias tool should not include funding source as a standard item.
    Sterne JA
    Cochrane Database Syst Rev; 2013 Dec; 2013(12):ED000076. PubMed ID: 24575440
    [No Abstract]   [Full Text] [Related]  

  • 24. Implications of pharmaceutical industry funding on clinical research.
    Lexchin JR
    Ann Pharmacother; 2005 Jan; 39(1):194-7. PubMed ID: 15562137
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Scientific harassment by pharmaceutical companies: time to stop.
    Hailey D
    CMAJ; 2000 Jan; 162(2):212-3. PubMed ID: 10674057
    [No Abstract]   [Full Text] [Related]  

  • 26. Pharmaceutical company-sponsored drug trials: the system is broken.
    Gartlehner G; Fleg A
    J Clin Epidemiol; 2010 Feb; 63(2):128-9. PubMed ID: 19880288
    [No Abstract]   [Full Text] [Related]  

  • 27. Small study on industry trial sponsorship leads to big questions about quality and bias.
    Twombly R
    J Natl Cancer Inst; 2007 Jul; 99(13):988-90. PubMed ID: 17596566
    [No Abstract]   [Full Text] [Related]  

  • 28. Keeping 'em honest: the current crisis of confidence in antidepressants.
    Teboul E
    J Clin Psychiatry; 2011 Jul; 72(7):1015; author reply 1015-6. PubMed ID: 21824461
    [No Abstract]   [Full Text] [Related]  

  • 29. [Clinical researchers and pharmaceutical industry].
    Mees EJ
    Ned Tijdschr Geneeskd; 1999 Oct; 143(44):2217. PubMed ID: 10578416
    [No Abstract]   [Full Text] [Related]  

  • 30. How pharmaceutical industry funding affects trial outcomes: causal structures and responses.
    Sismondo S
    Soc Sci Med; 2008 May; 66(9):1909-14. PubMed ID: 18299169
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Commercial and non-commercial 'championing' of medications.
    Parry P
    Aust N Z J Psychiatry; 2010 Jun; 44(6):585. PubMed ID: 20482422
    [No Abstract]   [Full Text] [Related]  

  • 32. Medical research has 'black hole': negative results often fail to get published in journals; some blame drug industry.
    Hensley S; Abboud L
    Wall St J (East Ed); 2004 Jun; ():B3. PubMed ID: 15218882
    [No Abstract]   [Full Text] [Related]  

  • 33. [Openness in the cooperation between physicians and private corporations].
    Jørgensen J; Djurhuus JC
    Ugeskr Laeger; 2003 Apr; 165(16):1642-5. PubMed ID: 12756817
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Company tried to bar report that H.I.V. vaccine failed.
    Hilts PJ
    N Y Times Web; 2000 Nov; ():A24. PubMed ID: 12159838
    [No Abstract]   [Full Text] [Related]  

  • 35. [Something for something--physicians, drug industry and general welfare].
    Bro F; Olesen F
    Ugeskr Laeger; 2006 Nov; 168(46):3985. PubMed ID: 17125648
    [No Abstract]   [Full Text] [Related]  

  • 36. Capture-recapture is a potentially useful method for assessing publication bias.
    Bennett DA; Latham NK; Stretton C; Anderson CS
    J Clin Epidemiol; 2004 Apr; 57(4):349-57. PubMed ID: 15135835
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Independent clinical trials are imperative].
    Gøtzsche PC
    Ugeskr Laeger; 2005 Apr; 167(14):1491-4. PubMed ID: 15887740
    [No Abstract]   [Full Text] [Related]  

  • 38. [ACCOMPLISH and the risks with company sponsored clinical trials].
    Furberg C
    Lakartidningen; 2009 Feb 11-17; 106(7):450. PubMed ID: 19350775
    [No Abstract]   [Full Text] [Related]  

  • 39. Accounting for uncertainty about investigator bias: disclosure is informative.
    Greenland S
    J Epidemiol Community Health; 2009 Aug; 63(8):593-8. PubMed ID: 19596837
    [No Abstract]   [Full Text] [Related]  

  • 40. Discrepancy between results and abstract conclusions in industry- vs nonindustry-funded studies comparing topical prostaglandins.
    Alasbali T; Smith M; Geffen N; Trope GE; Flanagan JG; Jin Y; Buys YM
    Am J Ophthalmol; 2009 Jan; 147(1):33-38.e2. PubMed ID: 18760766
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.